Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Clinical Topics
View All
Addiction
Anxiety
Bipolar Disorder
Depression
Difficult to Treat Depression
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
Christoph Hiemke, Prof Dr
JCP
Systematic Review
Therapeutic Reference Range for Olanzapine
July 19, 2023
A therapeutic reference range of 20–40 ng/mL for oral and long-acting injectable olanzapine yields optimal treatment effects in schizophrenia spectrum disorders. Dose reduction is not needed above 40 ng/mL...
Katja Wesner
,
Christoph Hiemke
,
Niels Bergemann
, et al
JCP
Consensus Statement
Consensus on Monitoring Blood Antipsychotic Levels
May 19, 2020
The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
Georgios Schoretsanitis
,
John M. Kane
,
Christoph U. Correll
, et al
JCP
Original Research
Duloxetine Dosing Strategies and Smoking Status
September 4, 2018
Cigarette smoking is common among individuals depression, and smoking can affect the metabolism of antidepressant medications. Read this article to learn dosing strategies that physicians can employ when treating...
Marc Augustin
,
Georgios Schoretsanitis
,
Christoph Hiemke
, et al
JCP
Original Research
Venlafaxine and
O
-Desmethylvenlafaxine Concentrations in Plasma and Cerebrospinal Fluid
August 19, 2014
Michael Paulzen
,
Sarah Groppe
,
Simone C. Tauber
, et al
